Understanding Walgreens Debt Rating and Credit Risk

Walgreens, a well-known pharmacy chain, has a debt rating that's worth understanding. Its debt rating is a measure of its creditworthiness, and it's determined by credit rating agencies like Moody's and Standard & Poor's.

Walgreens' debt rating has been impacted by its significant debt levels, with over $15 billion in long-term debt as of 2020. This is a significant amount, and it's essential to consider when evaluating the company's credit risk.

Walgreens has been working to reduce its debt levels, with a goal of reducing its debt-to-equity ratio to 2.5 or lower by 2023. This is a notable goal, and it suggests that the company is taking steps to manage its debt and improve its creditworthiness.

Walgreens Boots Alliance's debt has been a major concern for investors and credit rating agencies. The company's aggressive acquisition strategy fueled a rapid rise in debt, with the 2010 purchase of Duane Reade alone adding $457 million to its debt.

This significant increase in debt led to S&P's first-ever downgrade in 2010. The 2012 acquisition of 45% of Alliance Boots more than doubled the company's debt to $6 billion, resulting in a downgrade to the B category by both S&P and Moody's.

Walgreens' subsequent acquisitions, including the full acquisition of Alliance Boots in 2014, further strained its balance sheet, increasing debt to between $17 billion and $19 billion. This led to repeated downgrades by Moody's, highlighting the company's persistent financial leverage.

In 2023, S&P and Moody's downgraded Walgreens again due to its weak credit metrics and cash flow. The company's debt has exceeded four times its EBITDA, a key indicator of financial health.

Despite its scale as the second-largest US drugstore retailer, Walgreens' commitment to debt repayment has been partially offset by its weak credit metrics and cash flow.

You might like: Moody's Debt Rating Scale

A rating downgrade can have serious consequences for Walgreens' financial stability. Moody's recent downgrade highlights concerns about WBA's ability to maintain financial strength and meet its debt obligations in challenging market conditions.

Increased borrowing costs can impact WBA's profitability and hinder future investments. This is because the company may face higher interest rates when borrowing money.

Reduced access to capital can limit WBA's growth potential. The downgrade could make it more difficult for WBA to raise capital for future investments or acquisitions.

Eroding investor confidence can lead to a decline in WBA's stock price and a decreased market valuation. This is a significant concern, as a lower credit rating can make it harder for the company to attract investors and raise capital.

Unresolved legal challenges, such as the ongoing opioid lawsuit settlements, have already led to over $5.7 Billion in settlement penalties. These penalties are expected to siphon off 5% of annual profits in payments over 15 years, further straining the company's finances.

Here are the potential consequences of a rating downgrade for WBA:

Managing debt is a crucial aspect of Walgreens' financial health. WBA's debt accumulation was fueled by its aggressive acquisition strategy, including the 2010 purchase of Duane Reade, which included $457 million of debt, and the 2012 acquisition of 45% of Alliance Boots, which more than doubled debt to $6 billion.

Explore further: Bbby Acquisition Co Llc

Walgreens has taken steps to effectively manage its debt, including strategic asset sales. In 2023, the company divested $1.85 billion in AmerisourceBergen Corp. shares and $674 million of Cencora shares, demonstrating its commitment to shedding non-core assets and freeing up valuable capital for debt reduction and future investments.

By reducing debt, Walgreens aims to improve its financial health and regain credit agency confidence. The company's current leverage remains a red flag, with a debt-to-EBITDA ratio of 5.5x, which has prompted S&P Global to place WBA on CreditWatch negative.

To reduce its debt, Walgreens is exploring options such as the potential sale of the Boots business. Previously valued by WBA at around $9 billion, such a move could significantly reduce debt and streamline operations, boosting overall profitability and financial health.

Here are some key statistics on Walgreens' debt:

By taking decisive action to manage its debt, Walgreens can improve its financial health and regain investor confidence.

Walgreens' debt restructuring presents a classic risk-reward dilemma for investors, with potential cost savings of $1.5 billion in annual cost savings from closing underperforming stores and reducing staff.

The company's ability to convert these cost savings into sustainable EBITDA growth is key to unlocking risk-adjusted returns. Its U.S. Healthcare segment showed a 7% sales increase, hinting at untapped potential.

However, the segment's adjusted EBITDA of $65 million pales against the $14.2 billion operating loss for fiscal 2024, underscoring the urgency of operational fixes. This highlights the challenges Walgreens faces in its healthcare ventures.

The company's debt load remains a significant liability, with a $13.7 billion debt load and a debt-to-EBITDA ratio that needs to be below 8x. Credit agencies will be watching closely for signs of improvement.

Walgreens' history of underperformance in healthcare ventures and opioid-related liabilities casts a long shadow, making it a high-stakes gamble for investors. The company's ability to meet its 2026 deleveraging targets will be crucial in determining its future success.

A different take: The Debt Snowball Method Involves . . .

Walgreens' debt rating is a concern for investors, with Moody's Investors Service downgrading the company's rating to Baa3 in 2020. This downgrade indicates a higher risk of default.

The pharmacy giant's increasing debt levels are a major contributor to this rating change. Walgreens' debt-to-equity ratio has risen significantly since 2015.

The COVID-19 pandemic has put additional pressure on Walgreens' finances, with the company facing declining sales and revenue. In 2020, Walgreens reported a net loss of $1.5 billion.

Despite these challenges, Walgreens is taking steps to improve its financial health. The company has implemented cost-cutting measures and is exploring strategic partnerships to reduce its debt burden.

Walgreens' ability to refinance its debt and maintain a stable cash flow will be crucial in determining its future debt rating. The company's financial performance will likely be closely monitored by investors and credit rating agencies.

Consider reading: How Much Will Debt Collectors Settle for

Walgreens is facing significant challenges that have impacted its debt rating. Rising labor costs and other operating expenses have continually squeezed WBA's profit margins.

The economic pressures of 2008 led to slower comparable store growth, negatively impacting revenue and profitability, resulting in two downgrades from Moody's. This was a turning point for the company.

Aggressive competition from traditional brick-and-mortar players and the rise of online pharmacy retailers like Amazon Pharmacy have changed consumer behavior, leading to decreased store foot traffic. This has negatively impacted sales and profitability.

WBA's strategic shift towards healthcare services has yet to translate into significant profitability. The huge costs associated with these initiatives are an additional factor contributing to the company's challenges.